Efficacy and Safety of Induction Benmelstobart Plus Anlotinib and Chemotherapy Followed by Concurrent Chemoradiotherapy and Benmelstobart Maintenance Versus Concurrent Chemoradiotherapy Followed by Benmelstobart Maintenance in Patients With Unresectable Stage III NSCLC

NCT07643350 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

152

Enrollment

OTHER

Sponsor class

Conditions

NSCLC

Interventions

BIOLOGICAL: Benmelstobart
DRUG: benmelstobart combined with chemotherapy and anlotinib

Sponsor

The Third Xiangya Hospital of Central South University